Trial Profile
Pharmacotherapy of late-life generalized anxiety disorder.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Escitalopram (Primary)
- Indications Generalised anxiety disorder
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms RELIEF
- 29 Sep 2020 Results of Secondary analyses of data from 2 clinical trials of antidepressant pharmacotherapy for GAD (n=91) and MDD (n=191) assessing Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants, published in the Journal of Clinical Psychiatry
- 21 Jan 2009 Results reported in JAMA: the Journal of the American Medical Association
- 08 Sep 2008 Primary outcome updated as reported by ClinicalTrials.gov.